{
    "nctId": "NCT05978648",
    "briefTitle": "Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy",
    "officialTitle": "A Prospective, Multi-cohort, Exploratory Phase II Study of Trilaciclib Combined With Standard Chemotherapy in The Adjuvant Treatment of Hormone Receptor (HR) Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 116,
    "primaryOutcomeMeasure": "Occurrence of Grade 3/4 neutropenia",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* age \u2265 18 years;\n* breast cancer meets the following criteria:\n\n  * Histologically or cytologically confirmed and adequately resected non-metastatic primary invasive breast cancer;\n  * Cohort A only: ER, PR negative (\\< 1% nuclear staining as assessed by immunohistochemistry \\[IHC\\]), HER2 negative (HER2/CEP17 ratio \\< 2.0 or mean HER2 gene copy number \\< 4 signals/nucleus detected by IHC 0 or 1 + or in situ hybridization \\[ISH\\]); patients with concurrent bilateral invasive disease met the inclusion criteria if both lesions were HR negative/HER2 negative.\n  * Cohort B only: ER, PR negative (\\< 1% nuclear staining as assessed by immunohistochemistry \\[IHC\\]); HER2 positive: HER2/CEP17 ratio \u2265 2.0 or HER2 gene copy number \u2265 4 signals/nucleus detected by IHC 3 + and ISH; HER2 gene copy number \u2265 6 signals/nucleus detected by IHC 3 + or 2 + and ISH); patients with concurrent bilateral invasive disease met the inclusion criteria if both lesions were HR negative/HER2 positive.\n  * Subjects must have positive lymph nodes or tumors \\> 2 cm;\n  * The interval between radical surgery and the first dose \u2264 60 days;\n* Eastern Cooperative Oncology Group (ECOG) performance score 0-1;\n* have appropriate organ function, meet the following criteria: (1) have appropriate bone marrow function: Hb \u2265 100 g/L (no ESA and blood transfusion within 14 days before the first dose); absolute neutrophil count (ANC) \u2265 2 \u00d7 10\\^9/L (no G-CSF within 14 days before the first dose); platelet count \u2265 100 \u00d7 10\\^9/L (no rhTPO/rhIL-11 and platelet transfusion within 14 days before the first dose); (2) appropriate liver and kidney function: alanine aminotransferase (ALT) \u2264 2.5 \u00d7 upper limit of normal (ULN), aspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN, total bilirubin (TBIL) \u2264 1.5 \u00d7 ULN, serum creatinine \u2264 1.5 \u00d7 ULN, endogenous creatinine clearance \\> 50 ml/min (Cockcroft-Gault formula); (3) appropriate cardiac function: left ventricular ejection fraction (LVEF) \u2265 55%;\n* Non-hematologic toxicities from prior surgical procedures recovered to \u2264 Grade 1 or baseline (except alopecia);\n* Females of childbearing potential agree to practice reliable contraception during the clinical trial and have a negative serum or urine pregnancy test within 7 days prior to dosing;\n* Voluntarily join this study and sign informed consent, have good compliance and are willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n* Prior neoadjuvant therapy (including chemotherapy, targeted therapy, immunotherapy, or radiotherapy);\n* History of other malignancy within 5 years prior to first dose, except basal cell carcinoma and cervical carcinoma in situ;\n* Any T4 or N2 or known N3 or M1 breast cancer;\n* Subjects who cannot receive or tolerate postoperative chemotherapy for various reasons;\n* Heart disease ineligible for epirubicin, docetaxel, trastuzumab/pertuzumab:\n\n  * Any documented history of myocardial infarction, congestive heart failure\n  * Angina pectoris requiring antianginal medication\n  * Grade 3 or 4 cardiac arrhythmia (NCI CTCAEv5.0)\n  * Clinically significant valvular heart disease;\n  * Poorly controlled hypertension (systolic blood pressure \\> 180 mmHg and/or diastolic blood pressure \\> 100 mmHg)\n* Known history of hypersensitivity to the drug components of this protocol;\n* Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}